Search
pacritinib (Vonjo)
Indications:
- cytopenic myelofibrosis
* accelerated FDA approval based on spleen volume reduction
Contraindication:
- no better than placebo in patients with severe Covid-19 [1]
Dosage:
- 200 mg BID
capsules 100 mg
Pharmacokinetics:
- metabolized by CYP3A4
Adverse effects:
- > 20%
- diarrhea, thrombocytopenia, nausea, anemia, peripheral edema
Drug interactions:
- CYP3A4 inhibitors may increase toxicity
- CYP3A4 inducers may decrease efficacy
Mechanism of action:
- inhibits JAK2 & IRAK1
- minimal JAK1 inhibition
General
small inhibitory antineoplastic agent (ib drug)
hematologic agent
Database Correlations
PUBCHEM correlations
References
- Cafardi J, Miller C, Terebelo H et al
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe
COVID-19. A Phase 2 Randomized Clinical Trial.
JAMA Netw Open. 2022;5(12):e2242918.
PMID: 36469321 Free article
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799198
- Vonjo (pacritinib) capsules
https://www.vonjo.com/hcp/